{"title": "Clinical trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2012-02-23", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|E.1 Medical condition or disease under investigation\n|\n|E.1.1||Medical condition(s) being investigated ||\n|\n|Prevention of disease caused by the Streptococcus pneumoniae capsular serotypes included in the protocol in children and adults.\n|\n|Prevenci\u00f3n de la enfermedad causada por los serotipos capsulares indicados en el protocolo de Streptococcus pneumoniae en ni\u00f1os y adultos.\n|\n|E.1.1.1||Medical condition in easily understood language ||\n|\n|Prevention of disease caused by the Streptococcus pneumoniae capsular serotypes included in the protocol in children and adults.\n|\n|Prevenci\u00f3n de la enfermedad causada por los serotipos capsulares indicados en el protocolo de Streptococcus pneumoniae en ni\u00f1os y adultos.\n|\n|E.1.1.2||Therapeutic area ||Diseases [C] - Virus Diseases [C02]\n|\n|MedDRA Classification\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||14.1\n|\n|E.1.2||Level ||PT\n|\n|E.1.2||Classification code ||10035728\n|\n|E.1.2||Term ||Pneumonia pneumococcal\n|\n|E.1.2||System Organ Class ||10021881 - Infections and infestations\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||14.1\n|\n|E.1.2||Level ||PT\n|\n|E.1.2||Classification code ||10054047\n|\n|E.1.2||Term ||Pneumococcal sepsis\n|\n|E.1.2||System Organ Class ||10021881 - Infections and infestations\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||14.1\n|\n|E.1.2||Level ||LLT\n|\n|E.1.2||Classification code ||10058886\n|\n|E.1.2||Term ||Pneumococcal bacteremia\n|\n|E.1.2||System Organ Class ||10021881 - Infections and infestations\n|\n|E.1.2 Medical condition or disease under investigation\n|\n|\n|\n|E.1.2||Version ||14.1\n|\n|E.1.2||Level ||PT\n|\n|E.1.2||Classification code ||10027253\n|\n|E.1.2||Term ||Meningitis pneumococcal\n|\n|E.1.2||System Organ Class ||10021881 - Infections and infestations\n|\n|E.1.3||Condition being studied is a rare disease || No\n|\n|E.2 Objective of the trial\n|\n|E.2.1||Main objective of the trial ||\n|\n|1.-To demonstrate that the safety profile of a single dose of V114 is acceptable.\n|\n2.-To compare serotype-specific IgG geometric mean concentrations (GMCs), as measured by Merck?s pneumococcal electrochemiluminescence (Pn ECL) assay between recipients of a single dose of V114 and a single dose of PNEUMOVAX? 23 for the 14 shared serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F), as measured at 1 month postvaccination.\n|1.Demostrar que el perfil de seguridad de una dosis \u00fanica de V114 es aceptable.\n|\n2.Comparar la media geom\u00e9trica de la concentraci\u00f3n (MGC) de IgG espec\u00edfica de cada serotipo, determinada mediante un an\u00e1lisis de EQL Pn, entre los receptores de una dosis \u00fanica de V114 y de una dosis \u00fanica de PNEUMOVAX?23 en relaci\u00f3n con los 14 serotipos compartidos (1, 3, 4, 5, 6B, 7F, 9V, 14,18C, 19F, 19A, 22F, 23F y 33F), medida un mes despu\u00e9s de la vacunaci\u00f3n.\n|E.2.2||Secondary objectives of the trial ||\n|\n|The GMT of the OPA responses at one month postvaccination in subjects who receive V114 will be noninferior to those in subjects who receive PNEUMOVAX? 23.\n|\n|Comparar las MGT mediante MOPA 4 en relaci\u00f3n con los 14 serotipos compartidos entre los receptores de una dosis \u00fanica de V114 y de una dosis \u00fanica de PNEUMOVAX?23 un mes despu\u00e9s de la vacunaci\u00f3n.\n|\n|E.2.3||Trial contains a sub-study || Yes\n|\n|E.2.3.1||Full title, date and version of each sub-study and their related objectives||\n|\n|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older. (Genetic DNA and Future Biomedical Research)\n|\n|Estudio multic\u00e9ntrico y doble ciego de la seguridad, tolerabilidad e inmunogenicidad de una vacuna antineumoc\u00f3cica conjugada (V114) en comparaci\u00f3n con una vacuna antineumoc\u00f3cica de polisac\u00e1ridos (PNEUMOVAX 23) y Prevenar 13 (vacuna antineumoc\u00f3cica conjugada 13-valente [prote\u00edna dift\u00e9rica CRM197]) en adultos sanos de 50 a\u00f1os o m\u00e1s de edad. (Gen\u00e9tico y Uso futuro de muestras)\n|\n|E.3||Principal inclusion criteria ||\n|\n|1.Man or woman in good health.\n|\n2.Age ?50 years.\n3.Informed consent signed and dated prior to any study procedures being performed. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in the Future Biomedical Research.\n4.Afebrile (<100.4oF [<38.0oC] oral or equivalent) for 72 hours prior to vaccination.\n5.Subject is able to read, understand, and complete the study questionnaires (i.e., the VRC).\n6.Subject is able to attend all scheduled visits and to comply with the study procedures.\n7.Subject is highly unlikely to conceive at any time from signing the informed consent through 6 weeks after receiving the last dose of the study vaccine, as indicated by at least one ?yes? answer to the following questions:\na.Subject is male.\nb.Subject is a female who agrees to remain abstinent or use (or have her partner use) 2 acceptable methods of contraception during the time period at any time from signing the informed consent through 6 weeks after receiving the study vaccine. Acceptable methods of birth control are: hormonal contraceptives, diaphragm with spermicide, intrauterine device (IUD), contraceptive sponge, condom, or vasectomy. Note that simultaneous use of 2 reliable forms of contraception is recommended.\nc.Subject is a female who is not of reproductive potential. A female subject who is not of reproductive potential is defined as: one who has either (1) reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle stimulating hormone [FSH] levels in the postmenopausal range as determined by a laboratory, or 12 months of spontaneous amenorrhea), (2) post-surgical bilateral oophorectomy and/or hysterectomy, or (3) bilateral tubal ligation.\n|1.Var\u00f3n o mujer con buena salud.\n|\n2.Edad ? 50 a\u00f1os.\n3.Consentimiento informado firmado y fechado antes de realizar ning\u00fan procedimiento del estudio. El sujeto tambi\u00e9n podr\u00e1 otorgar su consentimiento para investigaci\u00f3n biom\u00e9dica futura. No obstante, podr\u00e1 participar en el ensayo principal sin participar en la investigaci\u00f3n biom\u00e9dica futura.\n4.Afebril (< 38,0 \u00baC de temperatura bucal o equivalente) durante las 72 horas anteriores a la vacunaci\u00f3n.\n5.El sujeto sabe leer y es capaz de comprender y cumplimentar los cuestionarios del estudio (es decir, la TV).\n6.El sujeto puede acudir a todas las visitas programadas y cumplir los procedimientos del estudio.\n7.El sujeto tiene muy pocas posibilidades de concebir en cualquier momento desde la firma del consentimiento informado hasta 6 semanas despu\u00e9s de recibir la \u00faltima dosis de la vacuna del estudio, tal como indica la presencia de al menos una respuesta afirmativa a las siguientes preguntas:\na.El sujeto es un var\u00f3n.\nb.El sujeto es una mujer que acepta mantener la abstinencia o utilizar (o hacer que su pareja utilice) dos m\u00e9todos anticonceptivos aceptables durante el per\u00edodo comprendido entre la firma del consentimiento informado y 6 semanas despu\u00e9s de recibir la vacuna del estudio. Son m\u00e9todos anticonceptivos aceptables los siguientes: anticonceptivos hormonales, dispositivo intrauterino (DIU), diafragma con espermicida, esponja anticonceptiva, preservativo o vasectom\u00eda. Obs\u00e9rvese que se recomienda el uso simult\u00e1neo de dos m\u00e9todos anticonceptivos fiables.\nc.El sujeto es una mujer que no est\u00e1 en edad f\u00e9rtil. Las mujeres que no est\u00e1n en edad f\u00e9rtil son aquellas que: (1) han alcanzado la menopausia natural (definida como 6 meses de amenorrea espont\u00e1nea con concentraciones s\u00e9ricas de folitropina [FSH] dentro del intervalo posmenop\u00e1usico seg\u00fan lo determinado por un laboratorio, o 12 meses de amenorrea espont\u00e1nea), (2) se han sometido a una ovariectom\u00eda bilateral o histerectom\u00eda o (3) se han sometido a una ligadura de trompas bilateral.\n|E.4||Principal exclusion criteria||\n|\n|1.Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate vaccine.\n|\n2.Known hypersensitivity to any component of the pneumococcal conjugate vaccine or of the pneumococcal polysaccharide vaccine.\n3.Known or suspected immunocompromised persons, including persons with congenital immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure (most recent serum creatinine values in medical record ?3 mg/dL), nephrotic syndrome, or other conditions associated with immunosuppression, such as organ or bone marrow transplant.\n4.Functional or anatomic asplenia.\n5.History of autoimmune disease.\n6.Subject has a coagulation disorder contraindicating intramuscular vaccinations.\n7.Subject has evidence of dementia or other cognitive impairment.\n8.Subject has insufficient muscle mass in the deltoid muscle of either arm or an inability to grade limitation of arm movement as required with postvaccination clinical monitoring.\n9.Use of any immunosuppressive therapy (Note: topical and inhaled/nebulized steroids are permitted). Subjects on corticosteroids should be excluded if they are receiving or are expected to receive, in the period from 30 days prior to Visit 1 through Visit 2, systemic doses greater than required for physiological replacement, i.e., >20 mg of prednisone (or equivalent) daily and for >2 weeks. Excluded immunosuppressive therapies also include chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease.\n10.Any underlying illness that would complicate evaluation and completion of this study.\n11.Any licensed non-live vaccine administered within the 14 days prior to receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days following receipt of study vaccine. (Exception: Inactivated influenza vaccine may be administered during the study but must be given at least 7 days prior to receipt of the study vaccine or at least 15 days after receipt of the study vaccine.\n12.Subject has received a licensed live virus vaccine within 30 days prior of receipt of study vaccine or is scheduled to receive any other licensed vaccine within 30 days of receipt of study vaccine.\n13.Subject has received any vaccine containing diphtheria toxoid within 6 months prior to receipt of study vaccine.\n14.Prior receipt of a blood transfusion or blood products including immune globulin administered within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.\n15.Investigational drugs or vaccines received within the 2 months before receipt of study vaccine or is scheduled to receive an investigational drug or vaccines within 30 days of receipt of study vaccine..\n16.Subject intends to participate in another interventional clinical study anytime during the duration of the current clinical study (participation in an observational or safety surveillance study is acceptable).\n17.History of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture-positive pneumococcal disease.\n18.Subject has received antibiotic therapy for any acute illness within 72 hours before receipt of study vaccine.\n19.Subject is pregnant or breast-feeding, or expecting to conceive within the projected duration of the study.\n20.Subject resides in a nursing home or long-term care facility or requires semi-skilled nursing care. (A resident of a retirement community who is otherwise ambulatory could be eligible.)\n21.Any subject who cannot be adequately followed for safety according to the protocol.\n22.Subject is unlikely to adhere to study procedures, keep appointments, or is planning to relocate during the study.\n23.Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study.\n|1.Administraci\u00f3n previa de cualquier vacuna antineumoc\u00f3cica de polisac\u00e1ridos o vacuna antineumoc\u00f3cica conjugada.\n|\n2.Hipersensibilidad conocida a cualquier componente de la vacuna antineumoc\u00f3cica conjugada o la vacuna antineumoc\u00f3cica de polisac\u00e1ridos.\n3.Sospecha o certeza de inmunodepresi\u00f3n, lo que comprende la existencia de una inmunodeficiencia cong\u00e9nita, infecci\u00f3n por el VIH, leucemia, linfoma, enfermedad de Hodgkin, mieloma m\u00faltiple, neoplasia maligna generalizada, insuficiencia renal cr\u00f3nica (valores de creatinina s\u00e9rica m\u00e1s recientes en la historia cl\u00ednica ? 3 mg/dl), s\u00edndrome nefr\u00f3tico u otras afecciones que se asocian a inmunodepresi\u00f3n, como un trasplante de \u00f3rganos o de m\u00e9dula \u00f3sea.\n4.Asplenia funcional o anat\u00f3mica.\n5.Antecedentes de enfermedad autoinmunitaria.\n6.El sujeto tiene un trastorno de la coagulaci\u00f3n que contraindica la vacunaci\u00f3n intramuscular.\n7.El sujeto tiene signos de demencia u otro deterioro cognitivo.\n8.El sujeto presenta una masa muscular insuficiente en el m\u00fasculo deltoides del brazo o incapacidad para graduar la limitaci\u00f3n del movimiento del brazo tal como exige la vigilancia cl\u00ednica despu\u00e9s de la vacunaci\u00f3n.\n9.Uso de cualquier tratamiento inmunodepresor (nota: se permitir\u00e1n los esteroides t\u00f3picos e inhalados/nebulizados). Deber\u00e1 excluirse a los sujetos que tomen corticoides si reciben o se prev\u00e9 que reciban, entre los 30 d\u00edas antes de la visita 1 y la visita 2, dosis sist\u00e9micas superiores a las necesarias para la reposici\u00f3n fisiol\u00f3gica, es decir, > 20 mg diarios de prednisona (o equivalente) durante > 2 semanas. Entre los tratamientos inmunodepresores excluidos figuran tambi\u00e9n los quimioter\u00e1picos contra el c\u00e1ncer u otras enfermedades y los tratamientos asociados al trasplante de \u00f3rganos o de m\u00e9dula \u00f3sea o enfermedades autoinmunitarias.\n10.Toda enfermedad subyacente que podr\u00eda complicar la evaluaci\u00f3n y la finalizaci\u00f3n del estudio.\n11.Administraci\u00f3n de cualquier vacuna de microorganismos inactivados autorizada en los 14 d\u00edas anteriores a la recepci\u00f3n de la vacuna del estudio o previsi\u00f3n de administrar cualquier otra vacuna autorizada en los 30 d\u00edas siguientes a la recepci\u00f3n de la vacuna del estudio. (Excepci\u00f3n: la vacuna antigripal inactivada podr\u00e1 administrarse durante el estudio, pero deber\u00e1 hacerse al menos 7 d\u00edas antes o 15 d\u00edas despu\u00e9s de la recepci\u00f3n de la vacuna del estudio.)\n12.El sujeto ha recibido una vacuna de microorganismos vivos autorizada en los 30 d\u00edas anteriores a la recepci\u00f3n de la vacuna del estudio o est\u00e1 previsto que reciba cualquier otra vacuna autorizada en los 30 d\u00edas siguientes a la administraci\u00f3n de la vacuna del estudio.\n13.El sujeto ha recibido cualquier vacuna que contenga toxoide dift\u00e9rico en los 6 meses anteriores a la administraci\u00f3n de la vacuna del estudio.\n14.Recepci\u00f3n previa de una transfusi\u00f3n de sangre o hemoderivado, incluidas inmunoglobulinas administrada en los 6 meses anteriores a la recepci\u00f3n de la vacuna del estudio, o previsi\u00f3n de recibir una transfusi\u00f3n de sangre o hemoderivado en los 30 d\u00edas siguientes a la administraci\u00f3n de la vacuna del estudio. Las autotransfusiones de sangre no se consideran un criterio de exclusi\u00f3n.\n15.Recepci\u00f3n de f\u00e1rmacos o vacunas en investigaci\u00f3n en los 2 meses anteriores a la administraci\u00f3n de la vacuna del estudio o previsi\u00f3n de recibir f\u00e1rmacos o vacunas en investigaci\u00f3n en los 30 d\u00edas siguientes a la administraci\u00f3n de la vacuna del estudio.\n16.El sujeto tiene la intenci\u00f3n de participar en alg\u00fan otro estudio cl\u00ednico intervencionista en cualquier momento durante el presente estudio cl\u00ednico (la participaci\u00f3n en un estudio observacional o de vigilancia de la seguridad es aceptable).\n17.Antecedentes de enfermedad neumoc\u00f3cica invasora (hemocultivo positivo, cultivo positivo de l\u00edquido cefalorraqu\u00eddeo u otro sitio est\u00e9ril) o de cualquier otra enfermedad neumoc\u00f3cica con cultivo positivo.\n18.El sujeto ha recibido antibi\u00f3ticos para tratar una enfermedad aguda en las 72 horas anteriores a la administraci\u00f3n de la vacuna del estudio.\n19.La paciente est\u00e1 embarazada o en per\u00edodo de lactancia o espera concebir durante el per\u00edodo previsto del estudio.\n20.El sujeto se encuentra en una residencia o centro de asistencia a largo plazo o tiene necesidad de atenci\u00f3n de enfermer\u00eda semiespecializada. (Podr\u00e1n participar los residentes en un complejo habitacional para jubilados que, por lo dem\u00e1s, tienen capacidad de andar.)\n21.Todo sujeto que no pueda ser vigilado debidamente en cuanto a seguridad de acuerdo con el protocolo.\n22.Es poco probable que el sujeto cumpla los procedimientos del estudio o acuda a las citas, o tiene previsto mudarse durante el estudio.\n23.Cualquier otro motivo que, en opini\u00f3n del investigador, pueda interferir en la evaluaci\u00f3n exigida por el estudio.\n|E.5 End points\n|\n|E.5.1||Primary end point(s)||\n|\n|Ratio of serotype-specific pneumococcal capsular polysaccharide IgG GMCs [V114 / PNEUMOVAX? 23] in the Pn ECL assay at 1 month postvaccination for 14 common serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F)\n|\n|Comparar la media geom\u00e9trica de la concentraci\u00f3n (MGC) de IgG espec\u00edfica de cada serotipo, determinada mediante un an\u00e1lisis de EQL Pn, entre los receptores de una dosis \u00fanica de V114 y de una dosis \u00fanica de PNEUMOVAX?23 en relaci\u00f3n con los 14 serotipos compartidos (1, 3, 4, 5, 6B, 7F, 9V, 14,18C, 19F, 19A, 22F, 23F y 33F), medida un mes despu\u00e9s de la vacunaci\u00f3n\n|\n|E.5.1.1||Timepoint(s) of evaluation of this end point||\n|\n|Day 1 prior to vaccination and Day 30 postvaccination\n|\n|D\u00eda 1 antes de la vacunaci\u00f3ny d\u00eda 30 despu\u00e9s de la vacunaci\u00f3n\n|\n|E.5.2||Secondary end point(s)||\n|\n|Ratio of serotype-specific functional pneumococcal capsular polysaccharide antibody GMTs [V114 / PNEUMOVAX? 23] in the MOPA-4 assay at 1 month postvaccination for 14 common serotypes ((1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F)\n|\n|Comparar las MGT mediante MOPA-4 en relaci\u00f3n con los 14 serotipos compartidos (1, 3, 4, 5, 6B, 7F, 9V, 14,18C, 19F, 19A, 22F, 23F y 33F) entre los receptores de una dosis \u00fanica de V114 y de una dosis \u00fanica de PNEUMOVAX?23 un mes despu\u00e9s de la vacunaci\u00f3n.\n|\n|E.5.2.1||Timepoint(s) of evaluation of this end point||\n|\n|Day 1 prior to vaccination and Day 30 postvaccination\n|\n|D\u00eda 1 antes de la vacunaci\u00f3ny d\u00eda 30 despu\u00e9s de la vacunaci\u00f3n\n|\n|E.6 and E.7 Scope of the trial\n|\n|E.6||Scope of the trial\n|\n|E.6.1||Diagnosis|| No\n|\n|E.6.2||Prophylaxis|| Yes\n|\n|E.6.3||Therapy|| No\n|\n|E.6.4||Safety|| Yes\n|\n|E.6.5||Efficacy|| No\n|\n|E.6.6||Pharmacokinetic|| No\n|\n|E.6.7||Pharmacodynamic|| No\n|\n|E.6.8||Bioequivalence|| No\n|\n|E.6.9||Dose response|| No\n|\n|E.6.10||Pharmacogenetic|| No\n|\n|E.6.11||Pharmacogenomic|| No\n|\n|E.6.12||Pharmacoeconomic|| No\n|\n|E.6.13||Others|| Yes\n|\n|E.6.13.1||Other scope of the trial description||\n|\n|immunogenicity\n|\n|inmunogenidad\n|\n|E.7||Trial type and phase\n|\n|E.7.1||Human pharmacology (Phase I)|| No\n|\n|E.7.1.1||First administration to humans|| No\n|\n|E.7.1.2||Bioequivalence study|| No\n|\n|E.7.1.3||Other|| No\n|\n|E.7.1.3.1||Other trial type description||\n|\n|E.7.2||Therapeutic exploratory (Phase II)|| Yes\n|\n|E.7.3||Therapeutic confirmatory (Phase III)|| No\n|\n|E.7.4||Therapeutic use (Phase IV)|| No\n|\n|E.8 Design of the trial\n|\n|E.8.1||Controlled|| Yes\n|\n|E.8.1.1||Randomised|| Yes\n|\n|E.8.1.2||Open|| No\n|\n|E.8.1.3||Single blind|| No\n|\n|E.8.1.4||Double blind || Yes\n|\n|E.8.1.5||Parallel group|| No\n|\n|E.8.1.6||Cross over || No\n|\n|E.8.1.7||Other|| No\n|\n|E.8.2|| Comparator of controlled trial\n|\n|E.8.2.1||Other medicinal product(s)|| Yes\n|\n|E.8.2.2||Placebo || No\n|\n|E.8.2.3||Other|| Yes\n|\n|E.8.2.3.1||Comparator description||\n|\n|Prevenar 13?, PNEUMOVAX? 23\n|\n|Prevenar 13?, PNEUMOVAX? 23\n|\n|E.8.2.4||Number of treatment arms in the trial||3\n|\n|E.8.3||\nThe trial involves single site in the Member State concerned\n|| No\n|\n|E.8.4|| The trial involves multiple sites in the Member State concerned || Yes\n|\n|E.8.4.1||Number of sites anticipated in Member State concerned||2\n|\n|E.8.5||The trial involves multiple Member States|| Yes\n|\n|E.8.5.1||Number of sites anticipated in the EEA||14\n|\n|E.8.6 Trial involving sites outside the EEA\n|\n|E.8.6.1||Trial being conducted both within and outside the EEA|| Yes\n|\n|E.8.6.2||Trial being conducted completely outside of the EEA|| No\n|\n|E.8.6.3||If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned||\n|\n|Canada\n|\n|Israel\n|\n|United States\n|\n|E.8.7||Trial has a data monitoring committee|| Yes\n|\n|E.8.8||\nDefinition of the end of the trial and justification where it is not the last\nvisit of the last subject undergoing the trial\n||\n|\n|E.8.9 Initial estimate of the duration of the trial\n|\n|E.8.9.1||In the Member State concerned years||1\n|\n|E.8.9.1||In the Member State concerned months||2\n|\n|E.8.9.1||In the Member State concerned days||0\n|\n|E.8.9.2||In all countries concerned by the trial years||1\n|\n|E.8.9.2||In all countries concerned by the trial months||3\n|\n|E.8.9.2||In all countries concerned by the trial days||0\n|", "language": null, "image": null, "pagetype": null, "links": ["/help.html", "/ctr-search/search", "/joiningtrial.html", "/contacts.html", "/about.html", "/about.html", "/whatsNew.html", "/dataquality.html", "/doc/Sponsor_Contact_Information_EUCTR.pdf", "/natauthorities.html", "/links.html", "/index.html", "/about.html", "https://euclinicaltrials.eu/", "https://eudract.ema.europa.eu/docs/guidance/EudraCT%20FAQ_for%20publication.pdf", "/doc/How_to_Search_EU_CTR.pdf#zoom=100,0,0", "javascript:void(0)", "javascript:void(0)", "#", "javascript:$('#expand').click();window.print()", "javascript:void(0)", null, "results", "javascript:window.location.replace('#A')", "javascript:window.location.replace('#B')", "javascript:window.location.replace('#C')", "javascript:window.location.replace('#D')", "javascript:window.location.replace('#D8')", "javascript:window.location.replace('#E')", "javascript:window.location.replace('#F')", "javascript:window.location.replace('#G')", "javascript:window.location.replace('#N')", "javascript:window.location.replace('#P')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", "https://eudract.ema.europa.eu/contact.html", "/disclaimer.html", "https://euclinicaltrials.eu/", "http://www.ema.europa.eu", "http://www.hma.eu"]}